Bioactive Compounds and Therapeutic Targets in Prostate Cancer 2.0
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Bioactives and Nutraceuticals".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 20
Special Issue Editor
Interests: prostate cancer; phytochemicals; dietary alkaloids; prebiotics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Globally, prostate cancer is one of the leading causes of death in men. The routine intake of bioactive compounds from various sources such as plants, diet, and marine organisms could be potentially beneficial in reducing the incidence and rates of death, as prostate cancer is characterized by a long latency period from the initiation of prostatic intraepithelial neoplasia to the development of adenocarcinoma. Although androgen deprivation therapy is the mainstay treatment, there is increased risk of patients developing lethal castration-resistant prostate cancer and treatment-induced neuroendocrine prostate cancer, in addition to experiencing severe side effects. There is increasing evidence that bioactive compounds could serve as alternative treatments or could be used as an adjunct therapy with conventional treatments to improve the quality of life and longevity of patients.
This Special Issue invites the submission of original research and review articles focused on bioactive compounds that have targets including androgen receptor (AR), AR variants (e.g., AR-V7), PI3K/Akt, mTOR, NF-kB, TGFbeta, EMT, transcription factors (e.g., c-Myc, N-Myc, STAT3, STAT5), mTOR, Wnt-beta catenin, Notch1, HDAC, DNMT3, etc., in prostate cancer cells based on in vitro and in vivo studies.
Dr. Gnanasekar Munirathinam
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- prostate cancer
- androgen receptor
- AR-V7
- castration-resistant prostate cancer
- dietary alkaloids
- dietary antioxidants
- phenolic compounds
- terpenoids
- phytochemicals
- xanthones
- probiotics
- preclinical
- marine bioactive agents
- molecular target
- signaling pathways
